



Estimating the lives that could be saved by expanded access to weight-loss drugs

Abhishek Pandey^a , Yang Ye^a, Chad R. Wells^a , Burton H. Singer^{b,1} , and Alison P. Galvani^{a,1}

Contributed by Burton H. Singer; received June 28, 2024; accepted September 3, 2024; reviewed by David N. Fisman and Lior Rennert

Obesity is a major public health crisis in the United States (US) affecting 42% of the population, exacerbating a spectrum of other diseases and contributing significantly to morbidity and mortality overall. Recent advances in pharmaceutical interventions, particularly glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide, liraglutide) and dual gastric inhibitory polypeptide and GLP-1 receptor agonists (e.g., tirzepatide), have shown remarkable efficacy in weight-loss. However, limited access to these medications due to high costs and insurance coverage issues restricts their utility in mitigating the obesity epidemic. We quantify the annual mortality burden directly attributable to limited access to these medications in the US. By integrating hazard ratios of mortality across body mass index categories with current obesity prevalence data, combined with healthcare access, willingness to take the medication, and observed adherence to and efficacy of the medications, we estimate the impact of making these medications accessible to all those eligible. Specifically, we project that with expanded access, over 42,000 deaths could be averted annually, including more than 11,000 deaths among people with type 2 diabetes. These findings underscore the urgent need to address barriers to access and highlight the transformative public health impact that could be achieved by expanding access to these novel treatments.

obesity | diabetes | mortality | weight-loss drugs | drug access

Obesity remains a formidable public health crisis in the United States (US), contributing substantially to both morbidity and mortality (1). It is a major risk factor for various chronic diseases, including cardiovascular disease, type 2 diabetes, and myriad forms of cancer. For example, the risk of endometrial cancer in people with severe obesity is seven times higher compared with the rest of the population who are not overweight (2). Among many other causes of mortality and morbidity, obesity is a risk factor for poor medical outcomes from a plethora of infectious diseases, surgical-site infections, and nosocomial infections (3). Compounding the challenge, the obesity prevalence in the US is skewed toward the vulnerable populations, including those with lower socioeconomic status and limited insurance coverage (4). Adults with obesity are likely to spend over \$1,800 more in medical costs per year than those without obesity (5). Altogether, the economic burden of obesity is immense, with estimated annual medical costs exceeding \$170 billion (5).

Historically, the development of pharmaceutical interventions for weight-loss has been fraught with challenges, including safety concerns and limited efficacy (6). However, a paradigm shift has occurred with the discovery that drugs originally intended for diabetes management, particularly glucagon-like peptide-1 (GLP-1) and dual gastric inhibitory polypeptide and GLP-1 (GIP/GLP-1) receptor agonists, can induce substantial weight-loss (7). These next-generation medications, such as semaglutide, liraglutide, and tirzepatide, have demonstrated remarkable efficacy in clinical trials, resulting in weight reductions previously considered unattainable through pharmaceutical means alone (7). As a result, these medications are increasingly gaining approval from the US Food and Drug Administration (FDA) for the treatment of obesity, ushering in a new era in obesity management (8).

Semaglutide, initially approved in 2017 for type 2 diabetes as Ozempic, expanded its use in 2021 with FDA approval as Wegovy for chronic weight management. This approval is for individuals aged 12 and older with a body mass index (BMI) of 30 kg/m² or higher or a BMI between 27 to 30 kg/m² with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol. Tirzepatide, another medication in this class, received approval in 2022 for type 2 diabetes as Mounjaro and most recently in November 2023 as Zepbound for chronic weight management in adults with similar criteria to Wegovy.

Despite their promise, widespread access to these medications remains a critical barrier to addressing the escalating obesity epidemic in the US. While semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have demonstrated efficacy in reducing body weight, their high-cost, limited supply, and lack of comprehensive insurance coverage

Significance

While obesity is rarely listed as the primary cause of death, it exacerbates a range of other chronic and acute diseases, overall leading to deaths that would not otherwise have occurred in the absence of obesity. This study quantifies the mortality impact of limited access to novel and highly effective weight-loss medications in the United States. By highlighting the potential number of lives lost due to restricted access, our research underscores the urgent need for policy interventions to improve affordability and insurance coverage. The findings have significant implications for public health strategies to combat the obesity epidemic and reduce associated mortality.

Author affiliations: ^aDepartment of Epidemiology of Microbial Diseases, Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT 06510; and ^bDepartment of Mathematics, Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610

Author contributions: A.P., Y.Y., B.H.S., and A.P.G. designed research; A.P., Y.Y., and C.R.W. performed research; A.P., Y.Y., and C.R.W. analyzed data; and A.P., Y.Y., C.R.W., B.H.S., and A.P.G. wrote the paper.

Reviewers: D.N.F., University of Toronto Dalla Lana School of Public Health; and L.R., Clemson University College of Behavioral Social and Health Sciences.

The authors declare no competing interest.

Copyright © 2024 the Author(s). Published by PNAS. This open access article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](https://creativecommons.org/licenses/by-nc-nd/4.0/).

¹To whom correspondence may be addressed. Email: bhsinger@epi.yale.edu or alison.galvani@yale.edu.

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2412872121/-DCSupplemental>.

Published October 15, 2024.

severely limit their accessibility. Without insurance, the monthly cost of these drugs can exceed \$1,000, making them unaffordable for many patients (9). This is particularly concerning given that obesity prevalence is higher among economically disadvantaged populations, further entrenching health inequities.

Medicare, the largest US insurer for older adults, does not cover these medications solely for weight-loss, impacting many elderly individuals who could benefit from them (9–12). For those on Medicaid, coverage varies widely across states, often requiring patients to meet additional criteria. Additionally, private insurance coverage is inconsistent, especially as many Americans have inadequate insurance with high deductibles and copays they cannot afford. The cost barrier is further compounded by the ongoing need for these medications, as discontinuation often leads to weight regain, necessitating a long-term financial commitment from patients.

In this study, we quantify the potential reduction in annual mortality that could be achieved by scaling up the uptake of these innovative obesity medications. Utilizing established correlations between BMI and mortality risk, along with the obesity prevalence data, we estimate the number of lives that could be saved annually under the current and expanded uptake levels of weight-loss medications among individuals eligible under the FDA guidelines. The projections underscore the significant public health impact of these novel treatments, informing policy decisions and healthcare practices related to obesity management.

Results

In the US, more than 40% of adults are classified as obese (BMI ≥ 30 ; Fig. 1A). By applying the hazard ratio for mortality across different BMI categories relative to the normal BMI category (BMI: 18.5 to 25), we estimate that 49.6% of the total annual deaths in the US occur among individuals categorized as obese (BMI ≥ 30 ; SI Appendix, Table S1). According to FDA guidelines, more than 45% of the adult US population is eligible for the new

weight-loss drugs, encompassing everyone with a BMI of 30 and above, as well as individuals with diabetes with a BMI between 25 to 30 (Fig. 1A and B and SI Appendix, Table S8).

Considering insurance status, 54% of Medicaid recipients and 40% of uninsured individuals are eligible for weight-loss drugs (Fig. 1C). State-level variations in obesity and diabetes prevalence result in a range of 34 to 56% of the eligible population, with West Virginia and Mississippi having the highest per capita eligibility (Fig. 1D and SI Appendix, Table S3).

We estimated annual deaths averted under two scenarios: the current uptake and expanded access. The current uptake reflects the proportion of eligible individuals who are currently using the weight-loss drugs (Methods and SI Appendix, Table S9). In our expanded access scenario, we take into account that drug uptake is contingent upon eligibility, the ability to obtain healthcare services (13), and individual willingness to take the medication (Methods).

As individuals gain access to these drugs, the distribution of the population by BMI categories is expected to shift toward healthier BMI ranges. Accounting for the adherence rate of people who take obesity drugs (27.2%) (14) and diabetes drugs (48.9%) (15), we project how the US population's BMI distribution would shift. Projecting on the basis of current uptake, the change in population distribution by BMI categories is expected to be only marginal (Fig. 2), with approximately 1.8% of obese individuals lowering their BMI below 30 (SI Appendix, Table S4). However, if the uptake is scaled up to all eligible individuals who have the ability to avail health care, it would lead to a greater shift in the population distribution by BMI categories, with 10.6% of obese individuals moving to healthier BMI categories below 30 (SI Appendix, Table S5). Moreover, 16.6% of those severely obese (BMI ≥ 40) would reduce their BMI below 40 (SI Appendix, Table S5). Under a more optimistic scenario of higher willingness to take the drugs (89%) and 100% adherence rate, BMI distribution would shift substantially with 41.3% of obese individuals lowering their BMI below 30 (Fig. 2 and SI Appendix, Table S6).




Fig. 1. (A) Distribution of the US adult population across BMI categories. (B) Percentage of population eligible (solid) for weight-loss drugs and the current uptake rate (hatch). (C and D) Percentage of eligible population among insurance categories (C) and states (D).




Fig. 2. Distribution of the US population across BMI categories with various levels of uptake of weight-loss drugs among eligible individuals.

Based on the projected BMI distributions, we found that at the current uptake level, the total number of deaths in the US would be reduced by 8,592 deaths annually [95% Uncertainty Interval (UI): 8,580 to 8,604]. The majority of these averted deaths (71%) is expected to be among individuals with private insurance reflecting current inequity in drug access (Table 1). However, under expanded access, the number of lives saved could rise by 42,027 annually [95% UI: 41,990 to 42,064], of which 11,769 [95% UI: 11,707 to 11,832] would be among overweight and obese individuals with type 2 diabetes (Table 1). With the expanded access, 9,977 [95% UI: 9,958 to 9,997] deaths averted would be among Medicare beneficiaries and 2,804 [95% UI: 2,801 to 2,807] would be among uninsured. To account for the impact of socioeconomic factors on individuals' mortality risk beyond access to these drugs, we adjust individuals' mortality reduction based on their income status (*SI Appendix*). This leads to a conservative estimate of 32,906 [95% UI: 32,875 to 32,938] fewer annual deaths. In contrast, as many as 165,574 [95% UI: 165,421 to 165,727] annual deaths could be averted under the optimistic scenario of willingness and adherence.

Considering the geographic distribution of obesity and diabetes on a per capita basis, expanded access to weight-loss drugs among eligibles could lead to an annual mortality reduction of 9.6 to 15.7 deaths per 100,000 population. While all states could achieve a reduction of at least 9.6 deaths per 100,000 population, West Virginia, Mississippi, and Oklahoma are expected to experience the largest per capita reduction (Fig. 3). By solely expanding access to obese individuals without type 2 diabetes, more than 40% of

the states could still expect a reduction of more than 9.6 deaths per 100,000 population.

Discussion

As a major risk factor for several chronic diseases, obesity is a national public health crisis. Our findings highlight the immense promise of the new generation of weight-loss drugs to mitigate the mortality and morbidity associated with obesity and diabetes. We estimated that if everyone eligible had access to these weight-loss drugs, the obesity prevalence would decline from 42 to 38% (16), averting over 50,000 deaths every year. At the current level of uptake, our projections indicate that 8,592 lives would be saved annually, less than 17% of the deaths that could be averted if access were expanded.

Limited access stems from a combination of financial barriers, supply constraints, and restrictive insurance coverage. Although insurance typically covers these medications for diabetes treatment, coverage for weight-loss is less consistent, often requiring patients to pay out-of-pocket or face restrictive insurance policies (17). Furthermore, 25.6 million Americans are uninsured (18) and more than 80 million are inadequately insured (19). Currently those uninsured with diabetes or obesity have no access to these innovative weight-loss drugs, and access is challenging even for those with coverage. For example, despite the widespread need for these medications among elderly aged 65 and above, Medicare Part D only covers the medications for diabetes management or cardiovascular risk reduction (20). Our results show that expanded access to obesity

Table 1. Mortality averted under the current uptake and expanded access scenarios, stratified by age group, drug access, and insurance category

		Additional lives saved annually	
		No access to current uptake	Current to expanded access
		Mean [95% UI]	Mean [95% UI]
Age group	≥18	8,592 [8,580 to 8,604]	42,027 [41,990 to 42,064]
	18 to 64	7,745 [7,734 to 7,757]	32,049 [32,015 to 32,084]
	≥65	847 [843 to 851]	9,977 [9,958 to 9,997]
Drug access	Diabetes	2,670 [2,657 to 2,684]	11,769 [11,707 to 11,832]
	Obesity	5,922 [5,910 to 5,933]	30,257 [30,197 to 30,317]
Insurance category	Private	6,104 [6,096 to 6,113]	20,275 [20,252 to 20,298]
	Medicaid	1,641 [1,638 to 1,643]	8,970 [8,961 to 8,980]
	Medicare	847 [843 to 851]	9,977 [9,958 to 9,997]
	Uninsured	0 [0 to 0]	2,804 [2,801 to 2,807]




Fig. 3. (A) State-level annual deaths averted per 100,000 population. (B) Distribution of averted deaths per capita among overweight and obese individuals with type 2 diabetes and obese individuals without type 2 diabetes.

drugs among elderly would lead to 7,480 fewer annual deaths among them. Adults under 65 on Medicaid face a higher risk of obesity, with a 27% greater likelihood compared to those with private insurance (21). Accounting for this disproportionate burden, we estimate that if access to these medications were expanded, 8,970 annual deaths projected to be averted would occur among Medicaid beneficiaries. However, accessing these medications through Medicaid remains challenging and varies significantly by state.

While Ozempic is ostensibly covered for diabetes treatment under Medicaid in all states, access often involves additional steps, such as prior authorization or trying alternative medications first (22). Coverage for Wegovy, specifically for chronic weight management, is even more restricted under Medicaid (23, 24). Our state-level results demonstrate that high-burden states for obesity and diabetes such as West Virginia, Mississippi, and Oklahoma are likely to avert most per capita deaths by expanding access to all eligible. While Ozempic is covered under Medicaid for type 2 diabetes in these states, they all require prior authorization or step therapy (25–27). Access to Wegovy is similarly restricted, with Mississippi Medicaid not covering it for weight-loss alone.

Compounding the challenges is their current high price point. At present, the prices of these drugs are significantly more expensive in the US compared to other countries (28). In the absence of price reduction, widespread adoption of the weight-loss drugs among eligible individuals is likely to impose substantial place an extraordinary financial strain on the US healthcare system (22). Conversely, at more reasonable prices, the drugs have the potential to avert other healthcare costs for the system by alleviating myriad chronic diseases. Fortunately, manufacturing prices of these drugs are estimated to be far below their current selling prices (29). To address the concerns, the US Senate has initiated an investigation regarding the excessive profit margins (29, 30) of these life-changing medications to expand availability to a wider population (31).

Policy makers must also be cognizant of other concerns. The manufacturers have struggled to meet the growing demand for Ozempic and similar drugs, contributing toward their current limited access. While Novo Nordisk, the producer of both Ozempic and Wegovy, is investing heavily to increase production capacity, supply still falls short of the burgeoning demand (32, 33). The surge in demand for these highly profitable drugs has the potential to disrupt the supply chain of other essential diabetes medications that utilize similar

delivery devices, particularly in low- and middle-income countries (34). Access challenges have already created a market for counterfeit and compounded drugs (35, 36). Therefore, harnessing the full potential of these pharmaceutical innovations would require a multifaceted approach that achieves sufficient manufacturing capacity to meet the demand at an affordable pricing.

While our results are likely to be robust, several factors may influence them. For example, our estimates are based on available data regarding the effectiveness and utilization of these medications. Specifically, the hazard ratio for mortality stratified by BMI categories used in our calculations was based on a study among white adults in the US (37). However, another retrospective cohort study of US adults of all races found hazard ratios that are consistent with the estimates used for our study (38). Nonetheless, our estimates are conservative in many regards. For example, overweight individuals with a BMI between 27 and 30 are eligible for these weight-loss drugs if they have comorbidities such as diabetes, hypertension, or high cholesterol according to FDA guidelines. In our analysis, we conservatively only considered individuals in the overweight-II category (BMI 27.5 to 30) with type 2 diabetes as eligible. Also, we used data on semaglutide to parameterize the efficacy of these drug types. Initial data indicate that the most recently approved tirzepatide may be even more efficacious (39).

In our analysis of scaling up the uptake among eligible individuals, we explore the impact of these drugs when neither cost nor supply is a barrier to access. However, even if these barriers can be eliminated, access to healthcare may remain restricted for many Americans. For example, individuals in rural areas or impoverished urban areas may simply not have access to care providers or pharmacies. To account for this reality, we restricted the expanded uptake of these drugs to only those eligible individuals who have an established primary care provider or healthcare facility. While these drugs have demonstrated effectiveness and safety in clinical trials, their long-term safety profile is still under investigation (40). The ongoing uncertainty, concerns about long-term efficacy, potential weight regain (41), and the stigma of weight-loss medications (42) make patients and healthcare providers hesitant to adopt these treatments, affecting their overall uptake. Inclusion of willingness of individuals to take these drugs in our analysis was parameterized to reflect the current evidence and perceptions.

As the efficacy and safety profile of these drugs become well established in future, it may alter both eligibility and uptake.

We did not account for how the impact on obesity-related mortality might vary in the presence of specific health conditions, prevention-based interventions, or lifestyle modifications. The availability of comprehensive weight management programs that integrate prevention-based approaches with access to these drugs could be the most effective strategy to mitigate the repercussions of obesity. Such programs may also mean that not all eligible individuals would need to be on the drugs. Additionally, socioeconomic factors such as race and poverty may influence an individual's mortality risk beyond just access to these drugs. Although the impact of expanded uptake, after adjusting for income-based differences in mortality reductions, is lower than in our base-case scenario, it remains significant. Therefore, addressing existing socioeconomic disparities through sustained efforts must accompany the improved access.

Expanding access to obesity medications such as GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, and prioritizing obesity as the primary condition for treatment could significantly reduce mortality rates and alleviate the economic burden of obesity-related healthcare costs. The treatment of obesity often leads to improvements in other chronic diseases, including cardiovascular disease and diabetes, as well as diseases that reduce the quality of life, such as rheumatoid arthritis (43). Therefore, the long-term benefits of improved access could extend beyond mortality reduction, potentially decreasing obesity-related comorbidities. Even for acute infectious diseases, such as influenza and COVID-19, obesity is a major risk factor for elevated severity and mortality. Our findings provide compelling evidence for the transformative impact that expanded access to these medications could have on improving the public health of the nation. This underscores the urgency of addressing access barriers, including affordability, insurance coverage, and prescriber awareness. Such policies could galvanize a new era of American well-being and prosperity.

Methods

We first stratified the US population into seven categories based on their BMI: BMI < 18.5, BMI 18.5 to 25, BMI 25 to 27.5, BMI 27.5 to 30, BMI 30 to 35, BMI 35 to 40, and BMI ≥ 40 (37). We then expressed the annual mortality in the US as a linear combination of annual deaths in each BMI category, using hazard ratios of mortality for each category compared to the reference category (BMI: 18.5 to 25) (37). This allowed us to derive the annual mortality rates for individuals in each BMI category.

To assess the impact of new weight-loss drugs, we recalculated the annual mortality in the US by applying the BMI category-specific annual mortality rates to the new population distribution across various BMI categories resulting from the weight-loss associated with drug use.

We calculated the new BMI distribution resulting from drug use as follows. Anthropometric reference data from the Centers for Disease Control and Prevention (CDC) (44) provided the age- and gender-specific distribution of height, weight, and BMI. Through Monte Carlo sampling of height and weight for each age and gender group, we derived 1,000 US population-level samples indexed by weight, height, BMI, age, and gender. Each population sample includes 100,000 people representing the US population stratified across the seven BMI categories.

Next, with each population sample, we modeled the proportion of individuals in each BMI category who would lose weight using diabetes/obesity drugs and calculated their projected BMI. If the new BMI fell into a different BMI category, the individuals were moved accordingly, and the proportion of the total population in each BMI category was recalculated.

The proportion of individuals within a specific BMI category who experience weight-loss depends on multiple factors: the proportion of individuals eligible for weight-loss medications, the uptake among the eligibles, the adherence rate among those taking the drug, and the effectiveness of the drugs themselves. These medications can be prescribed for both obesity and type 2 diabetes, with varying eligibility criteria. According to FDA guidelines, obesity medications can be prescribed to individuals with a BMI of 30 or higher or to those with a BMI between 27 and 30 who have at least one obesity-related condition such as diabetes, hypertension, or high cholesterol. In contrast, all individuals with type 2 diabetes are eligible for diabetes medications and would experience weight-loss if their BMI is over 25. Therefore, everyone with a BMI of 30 and above is considered eligible for weight-loss drugs. Of individuals with a BMI between 25 and 30, only those with diabetes are considered eligible in our study.

We considered two scenarios: the current uptake and expanded access (SI Appendix, Fig. S1). We used survey studies, prescription data, and cohort studies to parameterize the current uptake rate of the drugs among eligible populations for obesity and for diabetes as 10.8% (45) and 10.7 to 13.6% (46, 47), respectively. Under the expanded access scenario, the provision for drugs is for everyone eligible. The uptake rate in this scenario required both eligible individuals' ability to avail healthcare and their willingness to take these drugs. Ability to avail healthcare was informed by CDC's National Center for Health Statistics data on the proportion of adults aged 18 and over with an usual place of healthcare based on their insurance category (13). Among the eligible individuals, overall 87.6% of them had an usual place of health care (13). Using data from the Kaiser Family Foundation's health tracking poll, we incorporated that the proportion of eligible individuals' willingness to use the drugs is 75% (48).

Under both scenarios, weight-loss resulting from the drug use was dependent on the adherence rate as well as drug efficacy. In accordance with the clinical trials, we incorporate an adherence rate of 48.9% for individuals with diabetes (15) and 27.2% for individuals taking drugs solely for weight-loss (14). Weight-loss drugs are associated with an average weight-loss of 16.9% in individuals without type 2 diabetes (7). For individuals with type 2 diabetes, the weight-loss is approximately 40% lower than that observed in those without diabetes (49).

We distributed the national estimates of averted deaths across insurance categories and US states, using the population size, proportion of individuals eligible for weight-loss drugs, and drug accessibility within each group as weights (SI Appendix). The proportion of the eligible population was calculated based on the prevalence of obesity, diabetes, and overweight/obesity among diabetic patients within each group.

For results stratified by insurance category, all adults aged 65 and over are on Medicare, while adults aged 18 to 64 are on Medicaid, private insurance, or are uninsured. Insurance coverage data for adults aged 18 to 64 were obtained from the CDC's National Health Interview Survey (50). The proportion of individuals eligible for obesity/diabetes drugs was informed by integrating the differential risks across insurance categories with national-level diabetes and obesity prevalence data (21, 44, 51, 52). Under the current uptake scenario, high-cost weight-loss drugs would be prohibitive for people without insurance, leading to no averted deaths among this cohort. Under the expanded access scenario, we modeled equity of drug accessibility across all insurance categories. For state-level results, we assumed equal drug accessibility across all states for both scenarios. We normalized state-level prevalence of obesity, diabetes prevalence, and overweight/obesity among diabetic patients to align with national-level data (53, 54).

Data, Materials, and Software Availability. All publicly available data used for the study along with computational code written in Python for analysis is publicly available at Github (55).

ACKNOWLEDGMENTS. A.P.G. acknowledges the support from Burnett Endowment and A.P., Y.Y., C.R.W., and A.P.G. support from the Notsew Orm Sands foundation. The funding source had no influence on the methodology, analysis, or interpretation of the results.

1. K. M. Flegal, B. K. Kit, H. Orpana, B. I. Graubard, Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis. *JAMA* **309**, 71–82 (2013).
2. National Cancer Institute, Obesity and Cancer (2022). <https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet>. Accessed 11 June 2024.
3. R. Huttunen, J. Syrjänen, Obesity and the risk and outcome of infection. *Int. J. Obes.* **37**, 333–340 (2013).

4. CDC, Adult obesity prevalence maps. Obesity (2024). <https://www.cdc.gov/obesity/php/data-research/adult-obesity-prevalence-maps.html>. Accessed 7 June 2024.
5. Z. J. Ward, S. N. Bleich, M. W. Long, S. L. Gortmaker, Association of body mass index with health care expenditures in the United States by age and sex. *PLoS One* **16**, e0247307 (2021).
6. G. Srivastava, C. M. Apovian, Current pharmacotherapy for obesity. *Nat. Rev. Endocrinol.* **14**, 12–24 (2018).

7. J. P. H. Wilding *et al.*, Once-weekly semaglutide in adults with overweight or obesity. *N. Engl. J. Med.* **384**, 989–1002 (2021).
8. K. H. Lewis, C. E. Sloan, D. H. Bessesen, D. Arterburn, Effectiveness and safety of drugs for obesity. *BMJ* **384**, e072686 (2024).
9. K. D. Young, The push for Medicare to cover weight-loss drugs: An explainer. The Journalist's Resource (2023). <https://journalistsresource.org/home/semaglutide-ozempic-wegovy-weight-loss-drugs-research/>. Accessed 6 May 2024.
10. S. Sidik, Beyond Ozempic: Brand-new obesity drugs will be cheaper and more effective. *Nature* **619**, 19 (2023).
11. J. Cubanski, T. Neuman, N. Sroczynski, A. Damico, A new use for Wegovy opens the door to Medicare coverage for millions of people with obesity. KFF (2024). <https://www.kff.org/medicare/issue-brief/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/>. Accessed 6 May 2024.
12. Y. Noguchi, FDA approves Zepbound, a new obesity drug that will take on Wegovy. HEALTHNEWSFL (2023). <https://health.wusf.usf.edu/npr-health/2023-11-08/fda-approves-zepbound-a-new-obesity-drug-that-will-take-on-wegovy>. Accessed 6 May 2024.
13. National Center for Health Statistics, Percentage of angina for adults aged 18 and over, United States, 2019–2023. National Health Interview Survey (2024). https://wwwn.cdc.gov/NHISDataQueryTool/SHS_adult/index.html. Accessed 12 August 2024.
14. P. P. Gleason *et al.*, Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. *J. Manag. Care Spec. Pharm.* **30**, 860–867 (2024).
15. R. Mody *et al.*, Greater adherence and persistence with injectable dulaglutide compared with injectable semaglutide at 1-year follow-up: Data from US clinical practice. *Clin. Ther.* **44**, 537–554 (2022).
16. CDC, Adult obesity facts. Obesity (2024). https://www.cdc.gov/obesity/php/data-research/adult-obesity-facts.html?CDC_AAref_Val=https://www.cdc.gov/obesity/data/adult.html. Accessed 5 June 2024.
17. K. K. McCrimmon, Wegovy vs. Ozempic: The truth about new “weight-loss” drugs. UCHHealth Today (2023). <https://www.uchealth.org/today/wegovy-vs-ozempic-the-truth-about-new-weight-loss-drugs/>. Accessed 7 June 2024.
18. J. Tolbert, P. Drake, A. Damico, Key facts about the uninsured population. KFF (2023). <https://www.kff.org/uninsured/issue-brief/key-facts-about-the-uninsured-population/>. Accessed 21 June 2024.
19. S. R. Collins, L. A. Haynes, R. Masitha, The state of U.S. health insurance in 2022: Findings from the commonwealth fund biennial health insurance survey. (2022). <https://www.commonwealthfund.org/publications/issue-briefs/2022/sep/state-us-health-insurance-2022-biennial-survey>. Accessed 1 August 2024.
20. Bipartisan Policy Center, Expanding access to obesity treatments for older adults. <https://bipartisanpolicy.org/report/expanding-access-to-obesity-treatments-for-older-adults/>. Accessed 7 June 2024.
21. E. K. Mylona *et al.*, The association of obesity with health insurance coverage and demographic characteristics: A statewide cross-sectional study. *Medicine* **99**, e21016 (2020).
22. B. Deese, J. Gruber, R. Cummings, Opinion. *The New York Times*, 24 March 2024. <https://www.nytimes.com/2024/03/04/opinion/ozempic-wegovy-medicare-federal-budget.html>. Accessed 1 August 2024.
23. F. Kritz, Does Medicaid cover anti-obesity medication? Verywell Health (2024). <https://www.verywellhealth.com/does-medicare-cover-anti-obesity-medication-8650269>. Accessed 8 June 2024.
24. Novo Nordisk, Ways to gain coverage for Wegovy™. <https://www.wegovy.com/coverage-and-savings/wegovy-coverage-options.html>. Accessed 8 June 2024.
25. West Virginia Bureau for Medical Services, Preferred drug list and coverage details. <https://dhhr.wv.gov/bms/BMS%20Pharmacy/Pages/Preferred-Drug-List.aspx>. Accessed 7 June 2024.
26. Home-Mississippi Division of Medicaid, Mississippi Division of Medicaid-(2013). <https://medicaid.ms.gov/>. Accessed 8 June 2024.
27. U.S. Department of Health and Human Services, Medicaid Pharmacy - Actual Acquisition Cost of Generic Prescription Drug Products (2024). <https://oig.hhs.gov/reports/all/2002/medicaid-pharmacy-actual-acquisition-cost-of-generic-prescription-drug-products/>. Accessed 1 August 2024.
28. A. Watt, Semaglutide: A price and HTA comparison between US and top European markets. Pharmaceutical Technology (2023). <https://www.pharmaceutical-technology.com/analyst-comment/semaglutide-price-comparison-us-europe/>. Accessed 7 June 2024.
29. M. J. Barber, D. Gotham, H. Bygrave, C. Cepuch, Estimated sustainable cost-based prices for diabetes medicines. *JAMA Netw. Open* **7**, e243474 (2024).
30. B. N. Ippolito, J. F. Levy, Estimating the cost of new treatments for diabetes and obesity (2023). <https://EconPapers.repec.org/RePEc:aei:journl:y:2023:id:100861913628>. Accessed 1 August 2024.
31. J. Ra, Sanders takes aim at US drug prices of Novo's Ozempic and Wegovy. Pharmaceutical Technology (2024). <https://www.pharmaceutical-technology.com/news/sanders-takes-aim-at-us-drug-prices-of-novos-ozempic-and-wegovy/>. Accessed 7 June 2024.
32. H. E. Klein, An ongoing crisis: Semaglutide shortage raises dual concerns for obesity and diabetes treatment. *AJMC* (2023). <https://www.ajmc.com/view/an-ongoing-crisis-semaglutide-shortage-raises-dual-concerns-for-obesity-and-diabetes-treatment>. Accessed 7 June 2024.
33. V. Etienne, Novo Nordisk investing \$6 billion to increase access to ozempic and Wegovy amid nationwide shortage. PEOPLE (2024). <https://people.com/novo-nordisk-investing-usd6-billion-to-increase-access-to-ozempic-wegovy-8642499>. Accessed 7 June 2024.
34. S. Nolen, South Africa runs out of insulin pens as global supply shifts to weight-loss drugs. *The New York Times*, 19 June 2024. <https://www.nytimes.com/2024/06/19/health/insulin-pens-south-africa-ozempic-wegovy.html>. Accessed 1 August 2024.
35. D. Blum, More people are overdosing on ozempic alternatives. *The New York Times*, 6 August 2024. <https://www.nytimes.com/2024/08/06/well/ozempic-semaglutide-overdose-risks.html>. Accessed 20 August 2024.
36. Center for Drug Evaluation, Research, FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. U.S. Food and Drug Administration (2024). <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain>. Accessed 24 June 2024.
37. A. Berrington de Gonzalez *et al.*, Body-mass index and mortality among 1.46 million white adults. *N. Engl. J. Med.* **363**, 2211–2219 (2010).
38. A. Visaria, S. Setoguchi, Body mass index and all-cause mortality in a 21st century U.S. population: A National Health interview survey analysis. *PLoS One* **18**, e0287218 (2023).
39. A. M. Jastreboff *et al.*, Tirzepatide once weekly for the treatment of obesity. *N. Engl. J. Med.* **387**, 205–216 (2022).
40. M. Lenharo, Anti-obesity drugs' side effects: What we know so far. *Nature* **622**, 682 (2023).
41. L. J. Aronne *et al.*, Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. *JAMA* **331**, 38–48 (2024).
42. A. Brewis, S. Trainer, No “easy” weight loss: don't overlook the social cost of anti-obesity drugs. Nature Publishing Group UK (2024). <http://doi.org/10.1038/d41586-024-00329-9>. Accessed 28 August 2024.
43. G. Kolata, Doctors test the limits of what obesity drugs can fix. *The New York Times*, 18 June 2024. <https://www.nytimes.com/2024/06/18/health/obesity-first-wegovy-zepbound-doctors.html>. Accessed 1 August 2024.
44. National Center for Health Statistics, Vital and Health Statistics (2021). https://www.cdc.gov/nchs/data/series/sr_03/sr03-046-508.pdf. Accessed 14 May 2024.
45. A. Montero, G. Sparks, M. Presiado, L. Hamel, KFF Health tracking poll May 2024: The Public's use and views of GLP-1 drugs. Kaiser Family Foundation (2024). <https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/>. Accessed 7 June 2024.
46. L. A. Eberly *et al.*, Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. *JAMA Health Forum* **2**, e214182 (2021).
47. A. A. Nargesi *et al.*, Patterns of medication use and prescription fills for cardioprotective anti-hyperglycemic agents in the United States. *bioRxiv* [Preprint] (2022). <https://www.medrxiv.org/content/10.1101/2022.01.31.22270187v1> (Accessed 1 August 2024).
48. A. Montero, G. Sparks, A. Kirzinger, I. Valdes, L. Hamel, KFF health tracking poll July 2023: The public's views of new prescription weight loss drugs and prescription drug costs. KFF (2023). <https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-july-2023-the-publics-views-of-new-prescription-weight-loss-drugs-and-prescription-drug-costs/>. Accessed 13 June 2024.
49. W. Ghun *et al.*, Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. *JAMA Netw. Open* **5**, e2231982 (2022).
50. National Center for Health Statistics, Health insurance coverage. (2023). <https://www.cdc.gov/nchs/fastats/health-insurance.htm>. Accessed 21 June 2024.
51. A profile of uninsured persons in the United States. (2008). https://cdn.pfizer.com/pfizercom/products/Profile_of_uninsured_persons_in_the_United_States.pdf. Accessed 21 June 2024.
52. Centers for Disease Control and Prevention, National diabetes statistics report. Diabetes (2024). <https://www.cdc.gov/diabetes/php/data-research/index.html>. Accessed 7 June 2024.
53. Distribution of body mass index among adults. KFF (2023). <https://www.kff.org/other/state-indicator/distribution-of-body-mass-index-among-adults/?currentTimeframe=0&selectedDistributions=overweight-bmi-250-299--obese-bmi-30-399--severely-obese-bmi-of-40-or-higher&sortM=7B%22colld%22-%22Location%22,%22sort%22-%22asc%22%27D>. Accessed 21 June 2024.
54. Centers for Disease Control and Prevention, United States diabetes surveillance system. <https://gis.cdc.gov/grasp/diabetes/diabetesatlas.html>. Accessed 21 June 2024.
55. A. Pandey, Y. Ye, C. R. Wells, B. H. Singer, A. P. Galvani, Estimating the lives that could be saved by expanded access to weight-loss drugs. GitHub. <https://github.com/jianan0099/ObesityInaccessibility>. Deposited 28 August 2024.